TSLA
Tesla
-- 421.060 PLTR
Palantir
-- 80.550 NVDA
NVIDIA
-- 134.700 AMD
Advanced Micro Devices
-- 119.210 OXY
Occidental Petroleum
-- 47.130 
NEWS
AC Immune Gets FDA Fast-Track Designation for Neurodegenerative Diagnostic Scan
AC Immune's partner, Life Molecular Imaging (LMI), has received Fast Track Designation from the FDA for the Tau-PET diagnostic [18F]PI-2620 in three neurodegenerative conditions: Alzheimer's disease (AD), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). PI-2620, currently in Phase 3 clinical development for detecting Tau pathology in AD, is a next-generation PET imaging agent. This designation aims to accelerate development and review, highlighting the importance of early and accurate diagnoses in neurodegenerative diseases.
The Fast Track status for PI-2620 follows similar designations for AC Immune's active immunotherapies ACI-35.030 and ACI-24.060, both in Phase 2. This recognition underscores AC Immune's leadership in developing precision therapeutics for neurodegenerative diseases and its commitment to improving patient care through early diagnosis and treatment.
The Fast Track status for PI-2620 follows similar designations for AC Immune's active immunotherapies ACI-35.030 and ACI-24.060, both in Phase 2. This recognition underscores AC Immune's leadership in developing precision therapeutics for neurodegenerative diseases and its commitment to improving patient care through early diagnosis and treatment.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment